KJ-16001 is under clinical development by Kukje Pharmaceutical Industry and currently in Phase III for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase III drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how KJ-16001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

KJ-16001 overview

KJ-16001 is under development for the treatment of dry eye disease. The drug candidate is administered through ophthalmic formulation and is an incrementally modified drug (IMD). The drug candidate is being developed based on the DDS platform technology.

Kukje Pharmaceutical Industry overview

Kukje Pharmaceutical Industry (Kukje) is a manufacturer and distributor of pharmaceutical products. The company’s offering products include cephalosporins, quinolones and tetracycline, aminoglycosides, macrolides, antifungal, antiviral agents and ophthalmic agents, adrenal corticosteroids, central nervous system agents and osteoporotic agents, antihistamines, Non-steroidal anti-inflammatory drugs, gastrointestinal agents, cardiovascular agents, antidiabetics, genitourinary agents, respiratory agents. Kukje also offers analgesics and antibiotics. It also operates a research and development laboratory. The company provides pharmaceutical products to domestic and international markets in the Asia Pacific, countries, the Middle East and Africa. Kukje is headquartered in Seongnam, South Korea.

For a complete picture of KJ-16001’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.